Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DERMA: GSK 2132231A (MAGE-A3 ASCI) in Resected Melanoma
NCT00796445Phase 3Terminated
- Sponsor
- GSK
- Start
- Dec 2008
- Primary completion
- Jan 2016
- Modality
- Vaccines & Immunotherapeutics, Peptides, Fc-Fusion Proteins
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial of astuprotimut-R in melanoma (2 arms), sponsored by GSK. Primary endpoint: Disease Free Survival at 5 years. Started Dec 2008; status: terminated.
02
Drugs
astuprotimut-R
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00796445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00796445.